NURIX THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 9Avg age 66Avg tenure 5.4y
AS
Arthur Sands
Chief Executive Officer
Age 64Since 2014-09-17Profile →
+13
Executives5
AS
Arthur Sands→
Chief Executive Officer
Age 64Since 2014-09-17
HH
Hans van Houte→
Director of Finance/CFO
Age 60Since 2016-02-29
SR
Seema Rogers→
Chief Tech/Sci/R&D Officer
—Since 2019-07-31
MC
Marine Champsaur→
Chief Tech/Sci/R&D Officer
—Since 2022-07-31
PO
Paula O’Connor→
Chief Tech/Sci/R&D Officer
—Since 2022-08-31
Board of directors9
AS
Arthur Sands→
Director/Board Member
Age 64Since 2014-09-17
DL
David Lacey→
Chairman
Age 73Since 2019-07-31
JG
Julia Gregory→
Chairman
Age 72Since 2024-05-19
JR
Judith Reinsdorf→
Director/Board Member
Age 62Since 2021-09-30
PS
Paul Silva→
Director/Board Member
Age 60Since 2021-09-30
ES
Edward Saltzman→
Director/Board Member
Age 71Since 2022-09-11
AK
Anil Kapur→
Director/Board Member
Age 56Since 2024-10-14
RB
Roy Baynes→
Director/Board Member
Age 71Since 2025-03-10
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| BlackRock Advisors LLC | 8.069 % | 8,344,076 |
| Redmile Group LLC | 7.478 % | 7,732,808 |
| Vestal Point Capital LP | 6.286 % | 6,500,000 |
| Deep Track Capital LP | 6.136 % | 6,345,244 |
| Fidelity Management & Research Co. LLC | 5.359 % | 5,541,271 |
Catalog · 2026-07-09
Registry officers14
| Name | Role | Since | Shares |
|---|---|---|---|
| Arthur Sands | Chief Executive Officer | 2014-09-17 | - |
| David Lacey | Chairman | 2019-07-31 | - |
| Hans van Houte | Director of Finance/CFO | 2016-02-29 | - |
| Julia Gregory | Chairman | 2024-05-19 | - |
| Marine Champsaur | Chief Tech/Sci/R&D Officer | 2022-07-31 | - |
| Paula O’Connor | Chief Tech/Sci/R&D Officer | 2022-08-31 | - |
| Seema Rogers | Chief Tech/Sci/R&D Officer | 2019-07-31 | - |
| Anil Kapur | Director/Board Member | 2024-10-14 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 34.36Range 25–45Analysts 14
25Mean 34.3645
- Strong buy 5
- Buy 8
- Hold 1
Broker actions40 of 160
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | 35 | 2026-10-13 |
| Oppenheimer | Maintained | Outperform | 32 | 2026-10-13 |
| Truist Securities | Maintained | Buy | 33 | 2026-10-13 |
| Baird | Maintained | Outperform | 36 | 2026-10-13 |
| Needham | Reiterated | Buy | 34 | 2026-10-13 |
| RBC Capital | Maintained | Outperform | 36 | 2026-08-10 |
| Needham | Reiterated | Buy | 34 | 2026-08-04 |
| Morgan Stanley | Maintained | Overweight | 38 | 2026-07-28 |
| UBS | Maintained | Buy | 31 | 2026-07-22 |
| Mizuho | Maintained | Outperform | 34 | 2026-07-13 |
| Truist Securities | Maintained | Buy | 34 | 2026-07-10 |
| RBC Capital | Maintained | Outperform | 33 | 2026-07-10 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.